Understanding your role in detecting, reducing and preventing the development of antimicrobial resistance (AMR) is key to combating this growing threat. Once we realize how our actions can impact AMR, we can then take appropriate actions to stop and reduce its development and spread.
The challenge is how to quickly determine which patients really need powerful drugs and which do not. Good antibiotic stewardship is a race against the clock. If patients need those drugs and don’t receive them in a timely manner, it may become too late to help them.
In 2015, the CRE strain of KPC (Klebsiella pneumonia carbapenemase) took the lives of seven patients at the National Institutes of Health Clinical Center near Washington, D.C. According to the CDC, the first reported CRE case occurred in a North Carolina Hospital in 2001, and since then, cases have been identified in 41 states.